Umbilical cord/placenta-derived mesenchymal stem cells to treat RA and RARS of MDS
Myelodysplastic Syndromes
Enrolment: 30 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Myelodysplastic Syndromes
Enrolment: 30 · Results not recorded
Aplastic Anemia
Enrolment: 30 · Results not recorded
Type 2 Diabetes
Enrolment: 30 · Results not recorded
Multiple Sclerosis · Secondary-Progressive Multiple Sclerosis
Enrolment: 5 · Results not recorded
Ankylosing Spondylitis
Enrolment: 10 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Single total body irradiation of 7 Gy using a Gammacell 300 unit for radiation enteropathy; a separate lethality experiment used 10 Gy total body irradiation
Human placenta-derived mesenchymal stem cells given before, after or both before and after irradiation reduced intestinal pathology and inflammation and raised survival after 10 Gy total body irradiation to 100 per cent at 9 days and 70 per cent at 15 days.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
Model: Hind limb ischaemia as a model of peripheral artery disease
Placenta-derived mesenchymal stem cells reduced acute muscle fibre apoptosis, lessened fibrosis and improved running capacity, with reduced inflammatory cell infiltration and pro-inflammatory cytokines and increased IL-10.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.